Results 31 to 40 of about 22,928 (253)
Dentistry Journal, 2018 The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients.
Vittorio Fusco +6 more
doaj +1 more source
Osteonecrosis of The Jaw; Medication- Related Osteonecrosis of the jaw (MRONJ)
SONDE (Sound of Dentistry), 2021 Sejak tahun 2004, dilaporkan terjadinya osteonecrosis of the jaw pada pasien osteoporosis yang mengkonsumsi bifosfonat, walaupun hal tersebut lebih sedikir dibandingkan kejadian osteonecrosis of the jaw pada penderita kanker yang mendapat terapi bifosfonat secara intravena.
openaire +2 more sources
Osteonecrosis of the jaw [PDF]
Australian Prescriber, 2013 I have recently attended a number of meetings with endocrinologists where they consistently state that the incidence of bisphosphonate-related osteonecrosis of the jaw associated with oral bisphosphonate treatment of osteoporosis is about 1 in 100 000. There is obviously a wide variation of opinion.
Graham McNally +2 more
openaire +1 more source
RANK-Ligand inhibitor associated osteonecrosis of the jaw
GMS Interdisciplinary Plastic and Reconstructive Surgery DGPW, 2013 Osteonecrosis of the jaw may be caused by many different triggers. One of them is described to be the drug or medication related osteonecrosis of the jaw. Since many years bisphosphonates induced the dreaded diagnosis.
Rashad, Ashkan +2 more
doaj +1 more source
The establishment of a bisphosphonate⁃related osteonecrosis of the jaw rat model
口腔疾病防治, 2017 With the wide use of bisphosphonates in bone diseases such as osteoporosis and bone metastases of ma⁃ lignant tumors, bisphosphonate⁃related osteonecrosis of the jaw has gained widely attention as a severe side effect. Ani⁃ mal model is a useful way to
LIU Jie, TANG Hua
doaj +1 more source
Intraosseous Squamous Cell Carcinoma Associated with Denosumab-Induced Osteonecrosis of the Jaw
Applied Sciences, 2021 Medication-related osteonecrosis of the jaw (MRONJ) has been associated with the use of different drugs administered in the treatment of malignant neoplasms or metastases and in antiresorptive therapies. Since 2010, denosumab, a monoclonal antibody whose
Sandra Bacián Martínez +13 more
doaj +1 more source
Pharmacogenomics of osteonecrosis of the jaw
Bone, 2019 Osteonecrosis of the jaw (ONJ) is a rare but serious drug induced adverse event, mainly associated with the use of antiresorptive medications, such as intravenous (IV) bisphosphonates (BPs) in cancer patients. In this review, we evaluated all the pharmacogenomic association studies for ONJ published up to December 2018.
Guang Yang +10 more
openaire +4 more sources
Japanese Dental Science Review, 2019 Summary: Generally, CT and MR images of antiresorptive agent-related osteonecrosis of the jaw (ARONJ)/medication-related osteonecrosis of the jaw (MRONJ) show nonspecific findings as seen in active osteomyelitis．However, there are some characteristics as
Akira Baba +6 more
doaj +1 more source
Bone metabolism and clinical study of 44 patients with bisphosphonate-related osteonecrosis of the jaws [PDF]
, 2012 Osteonecrosis of the jaws is a clinical entity described and linked to treatment with bisphosphonates in 2003. Its real incidence is unknown and it could increase due to the large number of patients treated with these drugs, and its cumulative effect on ...
Bocanegra Pérez, Sacramento +7 more
core +1 more source
Osteonecrosis of the jaws in patients treated with bisphosphonates [PDF]
, 2012 The literature describes an increasing presence of bisphosphonate-induced osteonecrosis of the jaws (ONJ), characterized by the exposure for over 8 weeks of necrotic bone in the maxillofacial region, after bisphosphonate therapy, in the absence of ...
Ata-Ali Mahmud, Fadi +3 more
core +1 more source